ISSN 1016-5169 | E-ISSN 1308-4488
pdf
Use of dabigatran in patients with non-valvular atrial fibrillation: answers to frequently asked questions [Turk Kardiyol Dern Ars]
Turk Kardiyol Dern Ars. 2013; 41(4): 25-33

Use of dabigatran in patients with non-valvular atrial fibrillation: answers to frequently asked questions

Onur Sinan Deveci1, Mesut Demir1, Mehmet Aksoy2
1Cukurova University Faculty of Medicine, Department of Cardiology, Adana, Turkey
2Gaziantep University Faculty of Medicine, Department of Cardiology, Gaziantep, Turkey

Vitamin K antagonists (VKA) were maintaining their position as the gold standard theraphy for stroke prevention in patients with non-valvular atrial fibrillation (AF) for years. As an alternative to VKA, the developed new-generation anticoagulant agents began to enter our daily practice more often. Nonetheless, with the increasing use of these agents, both patients and physicians are faced with different questions and clinical scenarios. This article is intended to respond to frequently asked questions related to a new generation anticoagulant agent: Dabigatran.


How to cite this article
Onur Sinan Deveci, Mesut Demir, Mehmet Aksoy. Use of dabigatran in patients with non-valvular atrial fibrillation: answers to frequently asked questions. Turk Kardiyol Dern Ars. 2013; 41(4): 25-33

Corresponding Author: Mesut Demir, Türkiye
Manuscript Language: Turkish


Journal Metrics

Journal Citation Indicator: 0.18
CiteScore: 1.1
Source Normalized Impact
per Paper:
0.22
SCImago Journal Rank: 0.348

Quick Search



Copyright © 2024 Archives of the Turkish Society of Cardiology



Kare Publishing is a subsidiary of Kare Media.